GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » ROC %

Beijing Luzhu Biotechnology Co (HKSE:02480) ROC % : -42.71% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Beijing Luzhu Biotechnology Co's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was -42.71%.

As of today (2025-04-04), Beijing Luzhu Biotechnology Co's WACC % is 10.22%. Beijing Luzhu Biotechnology Co's ROC % is -32.54% (calculated using TTM income statement data). Beijing Luzhu Biotechnology Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Beijing Luzhu Biotechnology Co ROC % Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co ROC % Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
ROC %
-62.83 -49.16 -46.64 -31.74

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROC % Get a 7-Day Free Trial -28.74 -28.29 -65.84 -42.71 -23.14

Beijing Luzhu Biotechnology Co ROC % Calculation

Beijing Luzhu Biotechnology Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-270.625 * ( 1 - 0% )/( (551.221 + 609.148)/ 2 )
=-270.625/580.1845
=-46.64 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1195.075 - 77.802 - ( 649.526 - max(0, 105.098 - 671.15+649.526))
=551.221

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1276.105 - 93.095 - ( 665.375 - max(0, 105.344 - 679.206+665.375))
=609.148

Beijing Luzhu Biotechnology Co's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-254.104 * ( 1 - 0% )/( (609.148 + 580.879)/ 2 )
=-254.104/595.0135
=-42.71 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1276.105 - 93.095 - ( 665.375 - max(0, 105.344 - 679.206+665.375))
=609.148

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1186.599 - 99.062 - ( 580.678 - max(0, 101.967 - 608.625+580.678))
=580.879

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Luzhu Biotechnology Co  (HKSE:02480) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Beijing Luzhu Biotechnology Co's WACC % is 10.22%. Beijing Luzhu Biotechnology Co's ROC % is -32.54% (calculated using TTM income statement data). Beijing Luzhu Biotechnology Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Beijing Luzhu Biotechnology Co ROC % Related Terms

Thank you for viewing the detailed overview of Beijing Luzhu Biotechnology Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Luzhu Biotechnology Co Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is its Core Product.
Executives
Kong Jian 2101 Beneficial owner
Zhang Yanping 2202 Interest of your spouse
Ma Jianan 2201 Interest of corporation controlled by you
Zhu Hai Heng Qin Lv Zhu Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Bei Jing Lv Zhu Kang Rui Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Bei Jing Sai Sheng Yao Ye Gu Fen You Xian Gong Si 2101 Beneficial owner
Bei Jing Yi Zhuang Er Qi Sheng Wu Yi Yao Chan Ye Tou Zi Ji Jin You Xian He Huo 2101 Beneficial owner
Bei Jing Yi Zhuang Sheng Wu Yi Yao Bing Gou Tou Zi Zhong Xin You Xian He Huo 2101 Beneficial owner
Tian Jin Sai Ding Fang De Zi Chan Guan Li Zhong Xin 2201 Interest of corporation controlled by you
Tian Jin Sai De Rui Bo Zi Chan Guan Li Zhong Xin 2201 Interest of corporation controlled by you
Bei Jing Yi Tang Sai Ying Ji Jin Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
China Construction Bank Corporation 2201 Interest of corporation controlled by you
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Peng Ling 2201 Interest of corporation controlled by you
Ma Biao 2201 Interest of corporation controlled by you

Beijing Luzhu Biotechnology Co Headlines

No Headlines